
|Videos|February 13, 2014
Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer
Author(s)Dawn Hershman, MD, MS
Dawn Hershman, MD, MS, medical oncologist, Columbia University Medical Center, discusses chemotherapy-induced peripheral neuropathy in breast cancer.
Advertisement
Clinical Pearls
Dawn Hershman, MD, MS, medical oncologist, Columbia University Medical Center, discusses chemotherapy-induced peripheral neuropathy in breast cancer.
- Chemotherapy-induced neuropathy is the most common dose-limiting side effect and there are not any effective therapies for treatment or prevention
- Patients take a variety of supplements or drugs in the hopes that it will help reduce the neuropathy
- Preclinical data has shown that patients who were taking supplements actually had worse neuropathy compared to patients who were taking a placebo
- Researchers analyzed carnitine levels in the blood to ensure that patients took the supplements​
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
3
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
4
Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma
5






























